Association of Genetic Variants With Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration.

ABSTRACT:

Importance

Visual acuity (VA) outcomes differ considerably among patients with neovascular age-related macular degeneration (nAMD) treated with anti-vascular endothelial growth factor (VEGF) drugs. Identification of pharmacogenetic associations may help clinicians understand the mechanisms underlying this variability as well as pave the way for personalized treatment in nAMD.

Objective

To identify genetic factors associated with variability in the response to anti-VEGF therapy for patients with nAMD.

Design, setting, and participants

In this multicenter genome-wide association study, 678 patients with nAMD with genome-wide genotyping data were included in the discovery phase; 1380 additional patients with nAMD were genotyped for selected common variants in the replica

SUBMITTER: Lores-Motta L 

PROVIDER: S-EPMC6142943 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature